Citadel Investment Advisory Inc. cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,398 shares of the conglomerate’s stock after selling 50 shares during the quarter. Citadel Investment Advisory Inc.’s holdings in Danaher were worth $1,056,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. GPS Wealth Strategies Group LLC purchased a new position in Danaher in the first quarter valued at about $25,000. Freedom Wealth Alliance LLC purchased a new position in Danaher in the fourth quarter valued at about $27,000. Chelsea Counsel Co. purchased a new position in Danaher in the fourth quarter valued at about $27,000. Silicon Valley Capital Partners acquired a new stake in shares of Danaher during the first quarter valued at about $29,000. Finally, Stone House Investment Management LLC acquired a new stake in shares of Danaher during the first quarter valued at about $32,000. 76.71% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Teri List sold 3,490 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $263.30, for a total transaction of $918,917.00. Following the sale, the director now owns 17,494 shares of the company’s stock, valued at $4,606,170.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Danaher news, Director Teri List sold 3,490 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $263.30, for a total value of $918,917.00. Following the transaction, the director now owns 17,494 shares of the company’s stock, valued at $4,606,170.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joakim Weidemanis sold 22,439 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $263.42, for a total value of $5,910,881.38. Following the completion of the transaction, the executive vice president now directly owns 88,689 shares in the company, valued at approximately $23,362,456.38. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,922 shares of company stock valued at $12,552,233. Insiders own 11.10% of the company’s stock.
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Tuesday, July 25th. The conglomerate reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.04. The company had revenue of $7.16 billion during the quarter, compared to the consensus estimate of $7.12 billion. Danaher had a return on equity of 15.03% and a net margin of 20.95%. Danaher’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.76 earnings per share. Analysts anticipate that Danaher Co. will post 8.84 earnings per share for the current year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, October 12th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, October 11th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. Danaher’s dividend payout ratio (DPR) is presently 12.68%.
Analyst Ratings Changes
Several analysts have recently weighed in on DHR shares. Royal Bank of Canada raised their target price on Danaher from $260.00 to $292.00 in a research note on Wednesday, July 26th. Stifel Nicolaus lowered their target price on Danaher from $250.00 to $240.00 and set a “hold” rating for the company in a research note on Wednesday, July 26th. Bank of America raised their target price on Danaher from $250.00 to $280.00 in a research note on Wednesday, July 26th. StockNews.com assumed coverage on Danaher in a research note on Tuesday, September 12th. They set a “hold” rating for the company. Finally, Raymond James lifted their price target on Danaher from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 26th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $289.79.
Check Out Our Latest Research Report on Danaher
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- How to Calculate Inflation Rate
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 9/11 – 9/15
- Best Stocks Under $5.00
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.